You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Long-acting paliperidone palmitate interim results of an observational study of its effect on hospitalization

Taylor, Davida,b; Olofinjana, Olubankea

International Clinical Psychopharmacology:
doi: 10.1097/YIC.0000000000000028
Original Articles

Paliperidone palmitate (PP) is a recently introduced long-acting atypical, or second-generation, antipsychotic. Published data on PP are currently limited to controlled trials and case reports. In this observational study, we followed up 200 consecutive patients prescribed PP in normal practice. After 1 year, 65% of patients were still receiving PP. The number of admissions to hospital in the year following PP initiation was 0.49/patient compared with 0.69/patient/year, 3 years before initiation (P=0.0001). The mean number of bed days fell from 38.78 to 23.09/patient/year over the corresponding period (P=0.0001). The median number of bed days 3 years before PP initiation was 21.50/year and in the year following PP initiation, it was 0. Outcomes were numerically but not statistically better in those continuing PP than in those who ceased PP within a year of initiation. PP was effective and well-tolerated and, given its positive effect on hospital bed days, broadly cost-effective.

Author Information

aPharmacy Department, Maudsley Hospital

bInstitute of Pharmaceutical Science, King’s College London, London, UK

Correspondence to David Taylor, PhD, Pharmacy Department, Maudsley Hospital, Denmark Hill, London SE5 8AZ, UK Tel: +44 20 3228 5040; fax: +44 20 3228 2337; e-mail:

Received October 21, 2013

Accepted December 12, 2013

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins